Curio Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

Curio Wealth’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$279	–	203
2026 Q1	$279	Buy	+1	New	+$288	﹤0.01%	662

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Curio Wealth's BIO Position: Q2 2026 in Review

Curio Wealth sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 1 share — an estimated $279 sold.

Curio Wealth first reported a position in BIO in Q1 2026 and held it in 1 quarter. The position peaked at $279 in Q1 2026. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Curio Wealth reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 1 Bio-Rad Laboratories Class A share in Q2 2026, an estimated $279.
Curio Wealth first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and held it in 1 quarter.
Curio Wealth's Bio-Rad Laboratories Class A position peaked at $279 in Q1 2026.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.